4-[3-(吡啶-4-基)-3-取代苯基丙烯酰]吗啉类化合物的合成及杀菌活性

为了寻找具有高活性的含吡啶杂环杀菌剂, 以烯酰吗啉为模板化合物, 以异烟酸为起始原料, 通过卤代反应、Friedel-Crafts酰基化反应、Wittig-Horner反应等, 将吡啶-4-基或2-氯吡啶-4-基引入到模板结构中, 设计合成了27个4-[3-(吡啶-4-基)-3-取代苯基丙烯酰]吗啉类化合物, 其结构通过1H NMR和元素分析确证. 对目标化合物的初步杀菌活性测定结果表明, 所有目标化合物对立枯丝核菌(Rhizoctonia solani Kuhn.)和掘氏疫霉菌(Phytophthora drechsler Tucker)均有较强的抑制作用, 其中4-20, 4-21, 4-22化合物对立枯丝核菌的EC50值分别为28.94, 5.27和0.87 μg/mL(对照药剂多菌灵为1.54 μg/mL, 烯酰吗啉为60.95 μg/mL); 对掘氏疫霉菌的EC50值分别为0.33, 0.27和0.09 μg/mL(对照药剂百菌清为20.39 μg/mL, 烯酰吗啉为0.24 μg/mL), 表明该类化合物具有重大的研究开发价值.     

4(6)-{2-[4-(2,3,4-三甲氧基苄基)哌嗪-1-基]-2-氧代乙氧基}芳甲酰胍类化合物的合成及其Na~+/H~+交换器1抑制活性

NHE1(Na+/H+交换器1)抑制剂对于心肌缺血再灌注损伤具有较好的保护作用.以苯(或吡啶)甲酰胍为母核,利用拼合原理,在苯(或吡啶)甲酰胍母环上引入4-(2,3,4-三甲氧基苄基)哌嗪-1-甲基,设计并合成了8个未见文献报道的目标化合物.其结构经MS,IR,1H NMR和元素分析确证.体外血小板肿胀模型(PSA)试验结果表明,大部分目标化合物显示出较好的NHE1抑制活性.     

3-甲硫基-4-氨基-5-(吡啶-3-基)-1,2,4-三唑席夫碱的合成及抗肿瘤活性

以4-氨基-5-(吡啶-3-基)-1,2,4-三唑硫醇(1)为原料,经与碘甲烷硫醚化得3-甲硫基-4-氨基-5-(吡啶-3-基)-1,2,4-三唑中间体2,中间体2再与芳香醛缩合得相应目标化合物3a-3g.合成新化合物的结构经元素分析、IR、1H NMR、MS测试技术确证.采用MTT法研究了目标化合物体外抑制人肝癌细胞株SMMC-7721和Bel-7402的活性.结果表明,所合成的7个新化合物中,化合物3c、3e、3f对上述2种细胞株均表现出显著的体外抗癌活性,其IC50(μmol/L)值分别为3.8、2.0、1.3和2.5、2.5、1.1.     

4-取代-1-(2-甲基-6-(吡啶-3-基)-烟酰)氨基脲类衍生物合成与生物活性研究（英文）

经分子杂交技术合成了一系列4-取代-1-(2-甲基-6-(吡啶-3-基)-烟酰)氨基脲类衍生物.采用噻唑蓝(MTT)比色法研究了目标化合物对人肝癌细胞(QGY-7703)、人肺癌细胞(NCl-H460)和乳腺癌细胞(MCF-7)的体外抗肿瘤活性.1-(2-甲基-6-(吡啶-3-基)烟酰基)-4-(2,4,6-三氯苯基)氨基脲(4n)显示了最优的活性,其半数抑制浓度(IC_(50))为8.89～11.45μmol/L.细胞体内的生物研究显示,4n药物处理能明显增加细胞体内PARP切割水平以及诱导QGY-7703肿瘤细胞的凋亡.     

4-碘-2-甲基吡啶的合成工艺研究

4-碘-2-甲基吡啶是一个重要的医药化工中间体。本文以2-甲基-4-硝基吡啶-N-氧化物为起始原料,经还原和Sandmeyer反应得到目标化合物,总收率为73.5%。目标化合物的结构经~1H NMR、~(13)C NMR和MS确证。经优化后的工艺具有原料廉价易得、操作简便、制备周期短且收率较高等优点,适合工业化生产。     

5,10,15,20-四(4-(4-吡啶)酮基)苯基卟啉的合成、表征及晶体结构

利用丙酸法合成了一种新的化合物5,10,15,20-四(4-(4-吡啶)酮基)苯基卟啉,并进行了IR,UV-Vis,MS及EA表征,探讨了试剂4-羟基吡啶的异构现象及合成方法。采用溶液结晶法得到了该卟啉分子的晶体,对其进行了X-射线单晶衍射及粉末衍射测定。结果表明:该晶体属于正交晶系,空间群为Fddd。相邻的卟啉分子通过吡啶环之间的π…π作用与其他卟啉分子相连形成二维层状结构。层与层之间进一步通过吡啶环与卟啉环之间的π…π作用而形成三维超分子结构。该化合物可以作为构建金属卟啉框架新材料(MPF)的良好配体。     

含1-[4-二-(4-氟苯)甲基]哌嗪官能团的硫代酰胺的合成及生物活性

以1-[二-(4-氟苯)甲基]哌嗪、端炔及单质硫为原料,应用吡啶为催化剂和溶剂,在80℃反应24h以18～84％的收率制得了17个含有1-[4-二-(4-氟苯)甲基哌嗪官能团的硫代酰胺衍生物3(a～q).合成的17个目标化合物通过熔点测定和质谱、红外光谱及氢(碳)核磁共振谱分析对其结构进行确证.并进行了体外抗肿瘤及抗菌...     

N-二异丙基磷酰化氨基酸-N-4-氨基吡啶衍生物的合成及对河豚毒素(TTX)解毒生物活性的研究

通过母体化合物4-氨基吡啶(4-AP)与N-二异丙基磷酰化氨基酸(DiPP-AA)在Ph3P和C2Cl6体系下的缩合反应,将具有生物活性的氨基吡啶环引入到磷酸化氨基酸结构中,设计、合成了5个N-二异丙基磷酰化氨基酸-N-4-氨基吡啶衍生物A1～A5.所有目标化合物均经IR,1H NMR,13C NMR,31P NMR,MS的表征.初步生物活性测试结果表明:目标化合物对河豚毒素(TTX)中毒的小鼠均有一定的解毒作用,并不同程度地延长了生存时间,而且毒性比母体化合物降低了.     

N-芳基-4-(吡啶-2-基)-5-(1H-1,2,4-三唑-1-基)噻唑-2-胺衍生物的合成及生物活性研究

利用Hantzsch反应合成了13个N-芳基-4-(吡啶-2-基)-5-(1H-1,2,4-三唑-1-基)噻唑-2-胺衍生物,所有化合物的结构均经1H NMR,MS及元素分析确证.研究发现,溶剂对不同取代基的目标化合物的合成影响很大.生物活性测试结果表明,化合物均具有一定的杀菌活性.其中,化合物6c对番茄早疫和苹果轮纹、化合物6g对番茄早疫、化合物6h对黄瓜黑腥及化合物6i对苹果轮纹均显示80%以上的杀菌活性.     

N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)酰胺类新化合物的合成及生物活性

以N-吡啶基吡唑甲酸和2-氨基-3-甲基苯甲酸为起始原料,经由亲核加成、环化和酰化等多步反应合成了一系列结构新颖的N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)酰胺类化合物.测试了所合成化合物的杀虫及抑菌活性,结果表明,新化合物大多化合物在200 mg·L^-1浓度下对东方粘虫(Mythimna separataWalker)具有一定的杀虫活性,尤其是N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)乙酰胺(8a)和N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)-3-氯-2,2-二甲基丙酰胺(8e)致死率可达70%;部分化合物在50 mg·L^-1浓度下对油菜菌核病菌的抑菌活性相对较好(54.5%~63.6%),优于triadimefon和chlorantraniliprole;部分化合物如N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)-3,3-二甲基丁酰胺80和N-(2-(5-(3-溴-1-(3-氯吡啶-2-基)-1H-吡唑-5-基)-1,3,4-噁二唑-2-基)-4-氯-6-甲基苯基)-4-氟苯甲酰胺(8h)对苹果轮纹病菌具有中等抑菌活性.值得注意的是,化合物8e的杀粘虫活性和对油菜菌核病菌的抑菌活性都较为突出,可用作新农药创制研究的新型参考结构.     

光学纯(S)-2-(苄氧酰氨基)-4-氧代丁酸苄酯的合成和结构表征

以L-蛋氨酸为起始原料,经甲基化、水解、羧基和氨基保护及氯铬酸吡啶嗡盐(PCC)氧化等6步反应,合成了高光学纯度的(S)-2-(苄氧酰氨基)-4-氧代丁酸苄酯。通过1HNMR、IR、MS和mp测试技术表征了其结构;分别用手性柱HPLC和旋光仪法测定了它的化学纯度和光学纯度(ee%值)分别为99.3%和99.5%,产物的总收率为30.0%。     

Evaluation and validation of an HPLC procedure for the determination of the positional isomeric impurity in 2-[4-(1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl)-phenyl]-2-methylpropionic acid

A high-performance liquid chromatographic (HPLC) procedure was evaluated for the determination of a positional isomeric impurity in bulk 2-[4-(1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl)-phenyl]-2-methylpropionic acid HCl drug substance. The use of a β-cyclodextrin bonded-phase column with a mobile phase of 20/80 (v/v) acetonitrile/water containing an ammonium acetate buffer at apparent pH 4.0 and a flow rate of 0.45 mL/min resulted in an excellent separation of the isomers. Ultraviolet detection was used at 220 nm. A recovery study of known spike levels (0.1 to 1.5% w/w) showed that the procedure was accurate. A two-day, two-column repeatability study showed consistent results with the test batch of the bulk compound. The level of impurity in the tested lot of the compound had a mean level of 0.32% (w/w) and a standard deviation of 0.038% (w/w, n = 5). The text was submitted by the author in English.     

A gradient HPLC test procedure for the determination of impurities and the synthetic precursors in 2-[4-(1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl)-phenyl]-2-methylpropionic acid

A gradient high-performance liquid chromatographic (HPLC) test procedure is developed and evaluated for its ability to establish the levels of impurities and remaining synthetic precursors in 2-[4-(1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl)-phenyl]-2-methylpropionic acid. A gradient program with a mobile phase of 0.02 M sodium phosphate buffer and 0.004 M sodium perchlorate in acetonitrile-water (approximately pH 2.5) is used with a Spherisorb C6 column. The acetonitrile composition is increased linearly from 40% to 65% over a 45-min period and held at 65% for 20 min. UV detection at 210 nm is used to quantitate all components. The procedure is validated for accuracy using spiked levels (0.1% to 1.5%, w/w) with two suspected impurities, the synthetic precursors. A multiday repeatability study using two different Spherisorb C6 columns and HPLC systems shows consistent impurity quantitation results with one production lot of the bulk compound.     

Optically active antifungal azoles. XIII. Synthesis of stereoisomers and metabolites of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456)

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone [(1R,2R)-1: TAK-456] is a new antifungal agent selected as a candidate for clinical trials. The three stereoisomers [(1S,2R)-, (1S,2S)- and (1R,2S)-1] of this compound were prepared as authentic samples to determine the enantiomeric and diastereomeric purity of TAK-456 as well as to compare their in vitro antifungal activity. Pharmacokinetic studies of TAK-456 using rats identified the existence of metabolites in the liver homogenate. The structures of the major metabolites were assigned as 4-hydroxy-2-imidazolidinone (3) and/or 5-hydroxy-2-imidazolidinone (4), based on HPLC and LC/MS/MS analyses. These hydroxylated compounds, 3 and 4, were prepared by reduction of the corresponding imidazolidinediones, 11 and 12, and confirmed to be identical to the metabolites by HPLC. In vitro antifungal activities of the three stereoisomers and the synthesized metabolites were considerably weaker than TAK-456.     

Synthesis,Crystal, Computational Study and Biological Activity of N-(1-(2,4-Dichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4-(N,N-dipropylsulfamoyl)benzamide

The title compound N-(1-(2,4-dichlorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-4-yl)-4-(N,N-dipropylsulfamoyl)benzamide was synthesized by the condensation of 4-(dipropylsulfamoyl)benzoic acid with 1-(2,4-dichlorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-4-amine. This intermediate was prepared from 5-amino-1-(2,4-dichlorophenyl)-1 H-pyrazole-4-carbonitrile by the condensation with triethyl orthoformate and then cyclisation with ammonium hydroxide solution in tetrahydrofuran at room temperature. The crystal structure of the title compound was determined. The optimized geometric bond lengths and bond angles obtained by using density functional theory(DFT) have been compared with X-ray diffraction values. In addition, the preliminary biological test showed that the compound possesses distinct effective inhibition on the proliferation of some cancer cell lines.     

Crystal Structure and Spectral Characters of 2-（4-Methylbenzoly）-3-（4-chlrolphenyl） -4-（1,2,4-triazole）-5-anilino-thiopene

1 INTRODUCTION The triazole derivatives were widely studied because they represent the largest group of modern fungicides and extensively used in both human and veterinary therapy and in agriculture[1～3]. For exam- ple, there are commercially available …     

Synthesis, Crystal Structure and Biological Activities of 2- （4-Fluorophenyl） -2-oxo-1-（1H-1,2,4-triazol-1-yl） ethyl morpholine-4-carbodithioate

The title compound, 2-（ 4-fluorophenyl ） -2-oxo-1-（ 1H-1, 2,4-triazol-1-yl ） ethyl morpholine-4-carbodithioate, was synthesized and its structure was confirmed by means of IR, MS, 1 H NMR and elemental analysis. The single crystal structure of the title compound was determined by X-ray diffraction. The preliminary biological test showed that the synthesized compound possesses some biological activities.     

9,9-二[4-(4-羧基苯氧基)苯基]呫吨的合成

在碘化亚铜、四丁基溴化铵和磷酸钾存在下,9,9-二(4-羟基苯基)呫吨(1)和4-甲基碘苯(2)于N,N-二甲基甲酰胺溶剂中发生Ullmann偶联反应,加热回流反应24 h,以95%的产率合成了中间体--9,9-二[4-(4-甲基苯氧基)苯基]呫吨(3),继而加入催化量的N-溴代丁二酰亚胺并在光照条件下,将中间体3氧化得到一种新型芳香族二羧酸--9,9-二[4-(4-羧基苯氧基)苯基]呫吨(4),其产率为84%,二步反应总收率为79.8%。 目标化合物4经1H NMR、13C NMR、IR和元素分析测试技术确定了其结构。 该法具有原料易得,操作简单,反应条件温和,收率高等优点。     

Reaction of (R)-(-)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) with guanosine

The reaction of a new antitumor platinum complex, (R)-(-)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)platinum(II) (1) with guanosine at room temperature in an aqueous solution was followed by proton nuclear magnetic resonance (1H-NMR) spectroscopy and high performance liquid chromatography (HPLC) at intervals. Both techniques showed that a new compound was formed by displacement of the 1,1-cyclobutanedicarboxylate moiety of 1 with two guanosines, and its 1H-NMR spectrum and HPLC chromatogram were proved to be identical with those of [(R)-(-)-2-aminomethylpyrrolidine]bis(N7-guanosine)platinum(II) (2), which was obtained upon successive treatment of (R)-(-)-2-aminomethylpyrrolidinedichloroplatinum(II) (3) with AgNO3 and 2 mol eq of guanosine in water. The binding sites of the platinum to the two guanosine moieties in 2 were confirmed by the pH dependence of the two G-H8 signals.     

Metabolism of 1-(3-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]-propyl)-3-(6-methoxypyridin-3-yl)-1-(2-trifluoromethylbenzyl)thiourea (YH3945), a novel anti-cancer drug, in rats using the 14C-labeled compound

The metabolism of a novel anti-cancer agent, 1-(3-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]-propyl)-3-(6-methoxypyridin-3-yl)-1-(2-trifluoromethylbenzyl)thiourea (YH3945), was investigated in rats. Bile, plasma, feces, and urine were collected and analyzed by a high-performance liquid chromatography (HPLC) system equipped with ultraviolet (UV), mass spectrometric, and radioactivity detectors. After intravenous dosing, mean radiocarbon recovery was 74.4 +/- 1.3% with 62.4 +/- 1.2% in the feces and 12.0 +/- 0.5% in the urine. Biliary excretion of the radioactivity for the first 24 h period was approximately 32%, suggesting that YH3945 is cleared by hepatobiliary excretion. YH3945 was extensively metabolized to 21 different metabolites including glucuronide conjugates, and structures of the metabolites were elucidated based on MS(n) and NMR spectral analyses. The major metabolic pathways in the rat were identified as O-demethylation of methoxypyridine, N-debenzylation of imidazole, and hydroxylation. Cyclic metabolites were also identified; concomitant demethylation in the methoxypyridine moiety and hydroxylation at the C16 position might destroy the chemical stability of the compound and subsequently lead to non-enzymatic cyclization. Cyclic metabolites were characteristic of YH3945, and a non-enzymatic reaction mechanism for the formation of cyclic metabolites was postulated.